Evidence map›Paper›PMID 32380062›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2020

Comprehensive Molecular Profiles of Functionally Effective MSC-Derived Extracellular Vesicles in Immunomodulation.

Hyemee Kim, Min Joung Lee, Eun-Hye Bae, Jin Suk Ryu, Gagandeep Kaur, Hyeon Ji Kim, Jun Yeob Kim, Heather Barreda, Sung Youn Jung, Jong Min Choi and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 3 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 3 syntheses or guidelines pooled it, 141 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Hyemee KimDepartment of Molecular and Cellular Medicine, Institute for Regenerative Medicine, College of Medicine, Texas A&M University, 1114 TAMU, 206 Olsen Boulevard, College Station, TX 77845, USA.
Min Joung LeeDepartment of Ophthalmology, Hallym University Sacred Heart Hospital, 22, Gwanpyeong-ro 170beon-gil, Dongan-gu, Anyang-si, Gyeonggi-do 14068, Korea.
Eun-Hye BaeDepartment of Molecular and Cellular Medicine, Institute for Regenerative Medicine, College of Medicine, Texas A&M University, 1114 TAMU, 206 Olsen Boulevard, College Station, TX 77845, USA.
Jin Suk RyuLaboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, Korea.
Gagandeep KaurDepartment of Molecular and Cellular Medicine, Institute for Regenerative Medicine, College of Medicine, Texas A&M University, 1114 TAMU, 206 Olsen Boulevard, College Station, TX 77845, USA.
Hyeon Ji KimLaboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, Korea.
Jun Yeob KimLaboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, Korea.
Heather BarredaDepartment of Molecular and Cellular Medicine, Institute for Regenerative Medicine, College of Medicine, Texas A&M University, 1114 TAMU, 206 Olsen Boulevard, College Station, TX 77845, USA.
Sung Youn JungDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Jong Min ChoiDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Taeko Shigemoto-KurodaDepartment of Molecular and Cellular Medicine, Institute for Regenerative Medicine, College of Medicine, Texas A&M University, 1114 TAMU, 206 Olsen Boulevard, College Station, TX 77845, USA.
Joo Youn OhLaboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, Korea; Department of Ophthalmology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea. Electronic address: bonzoo1@snu.ac.kr.
Ryang Hwa LeeDepartment of Molecular and Cellular Medicine, Institute for Regenerative Medicine, College of Medicine, Texas A&M University, 1114 TAMU, 206 Olsen Boulevard, College Station, TX 77845, USA. Electronic address: rlee@tamu.edu.
Texas A&M University · USSeoul National University Hospital · KRBaylor College of Medicine · USHallym University Sacred Heart Hospital · KRSeoul National University · KR

Funding

Extracellular Vesicles Produced by Mesenchymal Stem Cells as Novel Therapy for Autoimmune UveitisR01EY029350 · NEI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI LEE, RYANG HWA · 2019 to 2023
$1.8M
Therapeutic effects of MSC-derived extracellular vesicles on Sjögren's SyndromeR21DE027457 · NIDCR · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI LEE, RYANG HWA, LIU, FEI · 2018 to 2019
$408k
NEI NIH HHS R01 EY029350NIDCR NIH HHS R21 DE027457
6 · The paper itself

Abstract

Accumulating evidence indicates that mesenchymal stem/stromal cell-derived extracellular vesicles (MSC-EVs) exhibit immunomodulatory effects by delivering therapeutic RNAs and proteins; however, the molecular mechanism underlying the EV-mediated immunomodulation is not fully understood. In this study, we found that EVs from early-passage MSCs had better immunomodulatory potency than did EVs from late-passage MSCs in T cell receptor (TCR)- or Toll-like receptor 4 (TLR4)-stimulated splenocytes and in mice with ocular Sjögren's syndrome. Moreover, MSC-EVs were more effective when produced from 3D culture of the cells than from the conventional 2D culture. Comparative molecular profiling using proteomics and microRNA sequencing revealed the enriched factors in MSC-EVs that were functionally effective in immunomodulation. Among them, manipulation of transforming growth factor β1 (TGF-β1), pentraxin 3 (PTX3), let-7b-5p, or miR-21-5p levels in MSCs significantly affected the immunosuppressive effects of their EVs. Furthermore, there was a strong correlation between the expression levels of TGF-β1, PTX3, let-7b-5p, or miR-21-5p in MSC-EVs and their suppressive function. Therefore, our comparative strategy identified TGF-β1, PTX3, let-7b-5p, or miR-21-5p as key molecules mediating the therapeutic effects of MSC-EVs in autoimmune disease. These findings would help understand the molecular mechanism underlying EV-mediated immunomodulation and provide functional biomarkers of EVs for the development of robust EV-based therapies.

Indexed as

AnimalsCell Culture TechniquesCell DifferentiationCell ProliferationCells, CulturedC-Reactive ProteinDisease Models, AnimalExtracellular VesiclesGene Expression ProfilingHumansMesenchymal Stem CellsMiceMicroRNAsPentraxinsProteomicsSerial PassageC-Reactive ProteinMicroRNAsMIRN21 microRNA, humanmirnlet7 microRNA, humanPentraxinsSerum Amyloid P-ComponentTGFB1 protein, humanTransforming Growth Factor beta1

Identifiers

PMID32380062
PMCPMC7335740
OpenAlexW3018967490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.